A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.

Aung NaingJustin F GainorHans GelderblomPatrick M FordeMarcus O ButlerChia-Chi LinSunil SharmaMaria Ochoa de OlzaAndrea VargaMatthew TaylorJan H M SchellensHongqian WuHaiying SunAntonio P SilvaJason FarisJennifer MatarazaScott CameronTodd M Bauer

Published in: Journal for immunotherapy of cancer (2021)

NCT02404441.

Keyphrases

endothelial cells
open label
randomized controlled trial
study protocol